Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether anti-CD80 monoclonal antibody (IDEC-114) is
effective in the treatment of follicular B-cell non-Hodgkin's lymphoma. This drug has never
been studied in patients with lymphoma, however, it has been studied in psoriasis patients at
various dose levels and schedules.